Form 8-K - Current report:
SEC Accession No. 0001193125-24-144934
Filing Date
2024-05-22
Accepted
2024-05-22 16:05:03
Documents
17
Period of Report
2024-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d822638d8k.htm   iXBRL 8-K 31083
2 EX-1.1 d822638dex11.htm EX-1.1 223388
3 EX-4.1 d822638dex41.htm EX-4.1 69228
4 EX-5.1 d822638dex51.htm EX-5.1 7551
8 GRAPHIC g822638g0522065903866.jpg GRAPHIC 2495
  Complete submission text file 0001193125-24-144934.txt   548182

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fhtx-20240520.xsd EX-101.SCH 2857
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE fhtx-20240520_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fhtx-20240520_pre.xml EX-101.PRE 11712
20 EXTRACTED XBRL INSTANCE DOCUMENT d822638d8k_htm.xml XML 3772
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 24973216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)